Xiaoxiao Wang

Dr. Xiaoxiao Wang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
PLPingPing Long
PingPing Long
SLSiyu Li
Siyu Li
LPLingyun Pan
Lingyun Pan
YWYuanqiang Wang
Yuanqiang Wang
WCWanyi Chen
Wanyi Chen
XWXiaoxiao Wang
Xiaoxiao Wang
Objective: As a novel drug formulation, antibody drug conjugates (ADCs) are widely used in various types of cancer. However, clinically, there is a lack of attention to the CVD produced by them, as well as a lack of research on the real-world situation. Using the Food and Drug Administration Adverse Event Reporting System (FAERS) database, to ensure its clinical safety application, we analyzed post-marketing data on antitumor ADCs to identify risk factors and drugs associated with the risk of cardiovascular events.Research design and methods: We used OpenVigil 2.1 to conduct a database query for adverse events (AEs) reported to the FAERS database between the time the drug was launched and the second quarter of 2023. Cardiovascular adverse events (AEs) were grouped into fourteen narrow categories using the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs), and the reporting odds ratio (ROR) and the proportional reporting ratio (PRR) for reporting the association between different drugs and cardiovascular disease (CVD) risk were calculated.Results: In the FAERS database, 1863 AEs associated with CVD we studied were identified in patients receiving ADC therapy. Most reports came from people aged ≥65, but a significant number of cases were found to be unknown. The number of patients with antibody-drug conjugates (ADCs)-related CVD cases aged <18 years, 18–64 years, and≥ 65 years was 52 (2.79%), 586 (31.45%), and 613 (32.90%), respectively. The proportion of female patients (834, 44.77%) was higher than that of male patients (752, 40.37%). Death (770 reports), disability (9 reports), Hospitalization initial or prolonged (407 reports), and life-threatening reactions (187 reports). Of the 770 deaths reported, 103 (31.7%) were associated with brentuximab vedotin, 10 (24.4%) with sacituzumab govitecan, 22 (19.3%) with enfortumab vedotin, and 35 (34.7%) with trastuzumab emtansine.49 (41.2%) cases were associated with polatuzumab vedotin, 62 (29%) with trastuzumab deruxtecan, 423 (54.3%) with gemtuzumab ozogamicin, and 66 (38.8%) with inotuzumab ozogamicin. In a disproportionate number of SMQS, cardiac failure (n = 277) and embolic and thrombotic events, venous (n = 446) were the most frequently reported CVD-related AEs in ADCs.Conclusion: By mining the FAERS database, we provided relevant information on the association between ADC use and cardiovascular-associated AEs. ADCs were associated with increased cardiovascular toxicity, deserving distinct monitoring and appropriate management. Further research is needed to confirm these findings and assess causality.

27 December 2021 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
YZYan-Jing Zhang
Yan-Jing Zhang
SWSi-Si Wu
Si-Si Wu
XCXue-Mei Chen
Xue-Mei Chen
JPJing-Kui Pi
Jing-Kui Pi
YCYu-Fei Cheng
Yu-Fei Cheng
XWXiaoxiao Wang
Xiaoxiao Wang
As a highly efficient anticancer agent, doxorubicin (DOX) is used for treatment of various cancers, but DOX-induced oxidative damages contribute to a degenerative irreversible cardiac toxicity. Saikosaponin D (SSD), which is a triterpenoid saponin with many biological activities including anti-inflammatory effects and antioxidant properties, provides protection against pathologic cardiac remodeling and fibrosis. In the present study, we investigated the work of SSD for DOX-induced cardiotoxicity and the involved mechanisms. We observed that DOX injection induced cardiac injury and malfunction and decreased survival rate. Besides, DOX treatment increased lactate dehydrogenase leakage, cardiomyocyte apoptosis, and myocardium fibrosis and decreased the size of cardiomyocytes. Meanwhile, all the effects were notably attenuated by SSD treatment. In vitro, we found that 1 μM SSD could enhance the proliferation of H9c2 cells and inhibit DOX-induced apoptosis. It was found that the levels of malondialdehyde (MDA) and reactive oxygen species were significantly reduced by improving the activities of the endogenous antioxidative enzymes including catalase and glutathione peroxidase. Furthermore, SSD treatment could downregulate the DOX-induced p38 phosphorylation. Our results suggested that SSD efficiently protected the cardiomyocytes from DOX-induced cardiotoxicity by inhibiting the excessive oxidative stress via p38-MAPK (mitogen-activated protein kinase, MAPK) signaling pathway.

10 July 2025 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
SLSiyu Li
Siyu Li
WLWenrui Li
Wenrui Li
MCMengfei Cheng
Mengfei Cheng
XWXiaoxiao Wang
Xiaoxiao Wang
WCWanyi Chen
Wanyi Chen
Background: Anthracyclines are cornerstone chemotherapeutics, but cardiotoxicity limits their use. Objective: This study aims to evaluate the efficacy of various drugs in preventing and treating anthracycline-induced cardiotoxicity (AIC). Methods: We conducted an extensive search across seven databases to identify randomized controlled trials (RCTs) pertinent to the prevention and treatment of AIC with medications. Subsequently, a Bayesian Model-based network meta-analysis was performed in the R 4.4.0. Results: A total of 128 RCTs involving 10,431 cancer patients treated with anthracyclines and 78 drug regimens were included in this study. The network meta-analysis results showed that, compared with patients who did not receive cardioprotective drugs, those treated with Calcium Dibutyryladenosine Cyclophosphate (Mean Difference [95% Credible Interval], 8.760 [0.5917, 16.92]), Carvedilol (4.024 [0.5372, 7.656]), Carvedilol + Candesartan (7.934 [3.159, 12.91]), Compound Salvia Miltiorrhiza + Levocarnitine (9.087 [0.9160, 17.25]), Dexrazoxane (5.066 [2.589, 7.540]), Dexrazoxane + Cinobufacini (11.61 [4.590, 18.70]), Dexrazoxane + Shenqi Fuzheng (13.05 [4.640, 21.40]), Nicorandil (14.24 [5.122, 23.31]), Qiliqiangxin (11.38 [2.826, 19.91]), and Xinmai Long (6.371 [1.735, 11.02]) experienced less decrease in LVEF after chemotherapy. The SUCRA ranking results indicated that the most effective treatment option for preserving LVEF was Nicorandil (SUCRA 91.76%). Conclusion: Apart from Dexrazoxane, Carvedilol, a β-blocker, also appears to show significant potential in preventing AIC. Furthermore, our results indicate that there is insufficient evidence to support the beneficial effects of statins, Sildenafil, Ivabradine, Levocarnitine, N-acetylcysteine, Glutathione, Coenzyme Q10, Vitamin E, and Vitamin C in preventing LVEF decline and exerting a positive effect on the prevention of AIC.

29 October 2024 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
LPLingyun Pan
Lingyun Pan
LMLi Mu
Li Mu
HLHaike Lei
Haike Lei
SMSiwei Miao
Siwei Miao
XHXiaogang Hu
Xiaogang Hu
XWXiaoxiao Wang
Xiaoxiao Wang

11 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZTZongwei Tang
Zongwei Tang
HSHaichi Song
Haichi Song
LPLingyun Pan
Lingyun Pan
MZMin Zhang
Min Zhang
SLSiyu Li
Siyu Li
XWXiaoxiao Wang
Xiaoxiao Wang
Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) represent a class of targeted drugs that have changed the cancer therapy landscape. However, the anti-angiogenic effect of VEGFR-TKIs significantly increase the incidence of cardiovascular adverse events (AEs). In this study, we conducted a comprehensive analysis of VEGFR-TKI-related thromboembolic events (TEEs), using data from the FAERS database between the drug launch and the third quarter of 2023. Disproportionality analysis, including reporting odds ratio, proportional reporting ratio, bayesian confidence propagation neural network, and multi-item gamma poisson shrinker, were used to explore the correlation between VEGFR-TKIs and TEEs. The total number of reported TEEs was 2688, representing 2.98% of all AEs associated with VEGFR-TKIs. A total of 17 and 12 preferred terms of arterial and venous thromboembolic events were observed in 8 VEGFR-TKIs. Lenvatinib, a VEGFR-TKI with low selectivity and high potency, exhibited the strongest TEE signal. A tendency of an increased signal of disproportionate reporting of TEEs was observed in sorafenib, regorafenib, and sunitinib. Indication, gender, age, drug class, concomitant medication and AEs may influence the occurrence of VEGFR-TKI-related TEEs. This study illustrates that TEEs are highly associated with VEGFR-TKIs, emphasizing the importance of screening for the TEE risks during VEGFR-TKI therapy.

10 February 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YYYuhui Yang
Yuhui Yang
PLPingping Long
Pingping Long
YTYing Tuo
Ying Tuo
XWXiaoxiao Wang
Xiaoxiao Wang
Objective: This study aims to evaluate the hemorrhage risk in solid tumor patients receiving angiogenesis inhibitors (AGIs), immune checkpoint inhibitors (ICIs), and their combination using the FDA Adverse Event Reporting System (FAERS) database.Methods: Data from Q1 2011 to Q4 2023 were extracted from the FAERS database for solid tumor patients treated with AGIs, ICIs, or their combination. A disproportionality analysis was conducted by calculating the reporting odds ratio (ROR) and corresponding 95% confidence interval (CI), as well as the Proportional Reporting Ratio (PRR), to identify potential safety signals. To assess whether the hemorrhage risk is higher with combination therapy compared to monotherapy, additive and multiplicative models were employed to evaluate the interactions between combination and single-agent treatments.Results: The combination of AGIs and ICIs significantly increased the risk of hemorrhagic adverse events, particularly tumor and pulmonary hemorrhage. Hemorrhagic events were common in females (50.97%) and older patients (aged 64+), frequently occurring within the first 30 days of treatment (38.11%). Gingival hemorrhage (ROR 3, PRR 418.9) and tumor hemorrhage (ROR 9.65, PRR 1893.36) were most common in the AGI group, while tumor hemorrhage (ROR 9.49, PRR 1350.78) and pulmonary hemorrhage (ROR 2.6, PRR 98.97) were prominent in the ICI group. In the combination group, esophageal variceal hemorrhage (ROR 40.72, PRR 2344.72) and tumor hemorrhage (ROR 19.31, PRR 1056.63) exhibited significantly increased risks Additive and multiplicative models indicated that the excess risk (RDAB = 0.01025, P<0.001) and relative risk (RRAB = 1.99277, P<0.001) of combination therapy were significantly higher than those of monotherapy, suggesting a positive interaction between the drugs that further increases the risk of hemorrhage.Conclusion: Our study demonstrates that the combination of AGIs and ICIs significantly raises the risk of hemorrhage, underscoring the urgent need for enhanced monitoring protocols in clinical practice to improve treatment efficacy and safety.